SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021.

• Main Authors: Anthony O Etyang (Author), Ifedayo Adetifa (Author), Richard Omore (Author), Thomas Misore (Author), Abdhalah K Ziraba (Author), Maurine A Ng'oda (Author), Evelyn Gitau (Author), John Gitonga (Author), Daisy Mugo (Author), Bernadette Kutima (Author), Henry Karanja (Author), Monica Toroitich (Author), James Nyagwange (Author), James Tuju (Author), Perpetual Wanjiku (Author), Rashid Aman (Author), Patrick Amoth (Author), Mercy Mwangangi (Author), Kadondi Kasera (Author), Wangari Ng'ang'a (Author), Donald Akech (Author), Antipa Sigilai (Author), Boniface Karia (Author), Angela Karani (Author), Shirine Voller (Author), Charles N Agoti (Author), Lynette I Ochola-Oyier (Author), Mark Otiende (Author), Christian Bottomley (Author), Amek Nyaguara (Author), Sophie Uyoga (Author), Katherine Gallagher (Author), Eunice W Kagucia (Author), Dickens Onyango (Author), Benjamin Tsofa (Author), Joseph Mwangangi (Author), Eric Maitha (Author), Edwine Barasa (Author), Philip Bejon (Author), George M Warimwe (Author), J Anthony G Scott (Author), Ambrose Agweyu (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<h4>Background</h4>Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population. We conducted population-based serosurveys at three Health and Demographic Surveillance Systems (HDSSs) to determine the cumulative incidence of infection with SARS-CoV-2.<h4>Methods</h4>We selected random age-stratified population-based samples at HDSSs in Kisumu, Nairobi and Kilifi, in Kenya. Blood samples were collected from participants between 01 Dec 2020 and 27 May 2021. No participant had received a COVID-19 vaccine. We tested for IgG antibodies to SARS-CoV-2 spike protein using ELISA. Locally-validated assay sensitivity and specificity were 93% (95% CI 88-96%) and 99% (95% CI 98-99.5%), respectively. We adjusted prevalence estimates using classical methods and Bayesian modelling to account for the sampling scheme and assay performance.<h4>Results</h4>We recruited 2,559 individuals from the three HDSS sites, median age (IQR) 27 (10-78) years and 52% were female. Seroprevalence at all three sites rose steadily during the study period. In Kisumu, Nairobi and Kilifi, seroprevalences (95% CI) at the beginning of the study were 36.0% (28.2-44.4%), 32.4% (23.1-42.4%), and 14.5% (9.1-21%), and respectively; at the end they were 42.0% (34.7-50.0%), 50.2% (39.7-61.1%), and 24.7% (17.5-32.6%), respectively. Seroprevalence was substantially lower among children (<16 years) than among adults at all three sites (p≤0.001).<h4>Conclusion</h4>By May 2021 in three broadly representative populations of unvaccinated individuals in Kenya, seroprevalence of anti-SARS-CoV-2 IgG was 25-50%. There was wide variation in cumulative incidence by location and age.

Item Description

2767-3375
10.1371/journal.pgph.0000883